La Jolla Pharmaceutical Company (LJPC)
(Delayed Data from NSDQ)
$8.26 USD
+0.22 (2.74%)
Updated May 3, 2019 04:00 PM ET
After-Market: $8.27 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$8.26 USD
+0.22 (2.74%)
Updated May 3, 2019 04:00 PM ET
After-Market: $8.27 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Can GW Pharmaceuticals (GWPH) Deliver a Beat in Q2 Earnings?
by Zacks Equity Research
On GW Pharmaceuticals' (GWPH) second-quarter conference call, investor focus will be on the initial sales uptick of its newly launched anti-epileptic drug Epidiolex.
CannTrust (CTST) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
On CannTrust's (CTST) second-quarter earnings call, investor focus will be on the company's efforts to resolve matters regarding the non-compliant report issued by Health Canada.
La Jolla (LJPC) Secures Positive CHMP Opinion for Giapreza
by Zacks Equity Research
The CHMP recommends La Jolla's (LJPC) marketing application for Giapreza to treat refractory hypotension in adult patients with septic or distributive shock.
Implied Volatility Surging for La Jolla Pharmaceutical (LJPC) Stock Options
by Zacks Equity Research
La Jolla Pharmaceutical (LJPC) needs investors to pay close attention to the stock based on moves in the options market lately.
La Jolla Pharmaceutical (LJPC) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of 10.69% and -11.75%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
La Jolla Pharmaceutical (LJPC) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
La Jolla Pharmaceutical (LJPC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Do Options Traders Know Something About La Jolla Pharmaceutical (LJPC) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to La Jolla Pharmaceutical (LJPC) stock based on the movements in the options market lately.
La Jolla Pharmaceutical (LJPC) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of 3.98% and 2.82%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
La Jolla Pharmaceutical (LJPC) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of -5.76% and -35.64%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
La Jolla Pharmaceutical (LJPC) Surges: Stock Moves 11.1% Higher
by Zacks Equity Research
The shares of La Jolla Pharmaceutical (LJPC) rose 11.1% on Friday
Implied Volatility Surging for La Jolla Pharmaceutical (LJPC) Stock Options
by Zacks Equity Research
Investors in La Jolla Pharmaceutical (LJPC) need to pay close attention to the stock based on moves in the options market lately.
La Jolla Pharmaceutical (LJPC) is in Overbought Territory: What's Next?
by Zacks Equity Research
La Jolla Pharmaceutical Company (LJPC) has moved higher as of late, but there could definitely be trouble on the horizon for this company